Liquid biopsy for and mutation testing in advanced colorectal cancer patients: the Argentinean experience.

To analyze the frequency of and hotspot mutations in circulating tumor DNA (ctDNA) from patients with metastatic colorectal cancer (mCRC). Observational, descriptive and retrospective study in mCRC patients with available ctDNA-based genotype of , and . The frequencies of plasma mutations for , and were 34% (± 7), 4% (± 3) and 4% (± 3), respectively. Median overall survival of plasma-tested -mutated patients was 26.6 months (95% CI: 14.4-not estimable [NE]), while wild-type patients did not reach the median survival during follow-up. Median progression-free survival for wild-type and -mutated patients was 12 (95% CI: 7-NE) and 4 months (95% CI: 4-NE), respectively. Our work supports the utility of , and analysis in liquid biopsy from mCRC patients.